[HTML][HTML] Prognostic factors for recurrence in pituitary adenomas: recent progress and future directions
L Lu, X Wan, Y Xu, J Chen, K Shu, T Lei - Diagnostics, 2022 - mdpi.com
Pituitary adenomas (PAs) are benign lesions; nonetheless, some PAs exhibit aggressive
behaviors, which lead to recurrence. The impact of pituitary dysfunction, invasion-related …
behaviors, which lead to recurrence. The impact of pituitary dysfunction, invasion-related …
Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway
JH Lee, A Chinnathambi, SA Alharbi, OHM Shair… - Pharmacological …, 2019 - Elsevier
Epithelial mesenchymal transition (EMT) refers to a phenomenon through which epithelial
cells develop the metastatic and invasive potential, which are closely related to …
cells develop the metastatic and invasive potential, which are closely related to …
[HTML][HTML] Tumor-associated macrophages: new horizons for pituitary adenoma researches
C Han, S Lin, X Lu, L Xue, ZB Wu - Frontiers in endocrinology, 2021 - frontiersin.org
Macrophages are one of the most common infiltrating immune cells and an essential
component of tumor microenvironment. Macrophages and the soluble cytokines and …
component of tumor microenvironment. Macrophages and the soluble cytokines and …
[HTML][HTML] ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway
J Wang, Z Zhang, R Li, F Mao, W Sun, J Chen… - Biomedicine & …, 2018 - Elsevier
Pituitary adenomas are the second most common primary brain tumor with invasive
properties. We have previously identified that ADAM12 (a disintegrin and metalloprotease …
properties. We have previously identified that ADAM12 (a disintegrin and metalloprotease …
[HTML][HTML] Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial‑to‑mesenchymal transition
B Li, HB Zhu, GD Song, JH Cheng, CZ Li… - Oncology …, 2019 - spandidos-publications.com
The aim of the present study was to investigate the role and potential regulatory
mechanisms of cyclin B1 (CCNB1) in the proliferation, apoptosis and epithelial‑to …
mechanisms of cyclin B1 (CCNB1) in the proliferation, apoptosis and epithelial‑to …
Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA
KA Øystese, O Casar-Borota… - The Journal of …, 2017 - academic.oup.com
Abstract Context Nonfunctioning pituitary adenomas (NFPAs) are fairly common and require
a multidisciplinary approach. Reliable markers of a clinically aggressive course are lacking …
a multidisciplinary approach. Reliable markers of a clinically aggressive course are lacking …
[HTML][HTML] Epithelial–mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly
Epithelial-mesenchymal transition (EMT) is a dynamic process by which epithelial cells loss
their phenotype and acquire mesenchymal traits, including increased migratory and invasive …
their phenotype and acquire mesenchymal traits, including increased migratory and invasive …
[HTML][HTML] PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling
J Liu, J Wang, W Tian, Y Xu, R Li, K Zhao, C You… - Aging (Albany …, 2022 - ncbi.nlm.nih.gov
As the second most common primary intracranial neoplasms, about 40% of pituitary
adenomas (PAs) exhibit aggressive behaviors and resulting in poor patient prognosis. The …
adenomas (PAs) exhibit aggressive behaviors and resulting in poor patient prognosis. The …
A systematic review of molecular alterations in invasive non-functioning pituitary adenoma
Purpose Invasive non-functional pituitary adenomas (NFPAs) constitute 35% of NFPAs.
Despite a relatively large body of molecular investigations on the invasiveness of NFPA, the …
Despite a relatively large body of molecular investigations on the invasiveness of NFPA, the …
[HTML][HTML] Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in …
A Synowiec, K Brodaczewska, G Wcisło… - International Journal of …, 2023 - mdpi.com
Natural compounds, such as resveratrol (Res), are currently used as adjuvants for
anticancer therapies. To evaluate the effectiveness of Res for the treatment of ovarian …
anticancer therapies. To evaluate the effectiveness of Res for the treatment of ovarian …